May 29, 2020Open Access
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Key Points
Key points are not available for this paper at this time.
Abstract
Therapy with trastuzumab deruxtecan led to significant improvements in response and overall survival, as compared with standard therapies, among patients with HER2-positive gastric cancer. Myelosuppression and interstitial lung disease were the notable toxic effects. (Funded by Daiichi Sankyo; DESTINY-Gastric01 ClinicalTrials.gov number, NCT03329690.).
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
K
Kohei Shitara
University of Padua
Yung‐Jue Bang
Rutgers, The State University of New Jersey
S
Satoru Iwasa
Brazilian Medical Association
Journals
New England Journal of Medicine
Actions
Institutions
Seoul National University
Yonsei University
Sungkyunkwan University
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...